In vivo studies on lysosubtilin. 3. Efficacy for treatment of mastitis and superficial lesions of the udder and teats in cows.
Lysosubtilin is a broad-spectrum preparation of lytic enzymes from Bacillus subtilis designed for veterinary medicine. This study demonstrates its efficacy for the treatment of reproductive system diseases (mastitis, superficial lesions of the udder and teats) in cows. Prior to determination of optimal therapeutic doses, samples taken from the milk and udder skin of sick animals were examined microbiologically. The examinations revealed a high incidence of polymicrobial infections (26.9 and 84.9% for mastitis and superficial udder lesions, respectively) caused by various mixtures of bacteria (both Gram-positive and Gram-negative) and fungi/yeasts. Dose determination studies involved 115 cows with clinical signs of mastitis. The optimal dose for mastitis treatment was found to be 3.5 x 10(6) U lysosubtilin dissolved in 100 mL of distilled water, which was then administered into the mammary gland via the teat canal once daily until recovery. Such a dose yielded statistically significant decreases (P < 0.05) both in the length of time before clinical recovery (2 d versus 4 and 4.5 d with either of the two antibiotic-based traditional drugs) and in the percentage of animals who suffered relapses within a 2-month period following treatment (5% versus 60%, with one of the two drugs). A field experiment involving 106 cows was designed to compare the efficacy of 1% lysosubtilin water-glycerin solution (1:9 v/v) and other traditional medications for the topical treatment of superficial lesions of the udder and teats as well as its potential for mastitis prevention. All drugs used yielded a 100% cure rate, but lysosubtilin application made it possible to achieve a statistically significant decrease (P < 0.05) in the duration of the recovery period (2.5 d versus 4.5 to 5.5 d) when compared with any of the four other drugs tested. Its efficacy for mastitis prevention was at least 3.4 times higher than the efficacy of the other medications used (statistically significant, P < 0.05, with regards to two of the four drugs) as well. We therefore conclude that lytic enzyme preparations are prospective antimicrobial drugs and when used to combat animal diseases they may serve as a possible alternative to common antibiotics.
Sector of Immunobiotechnology, Institute of Immunology, Vilnius, Lithuania.
G A
GA
Biziulevichius
K
K
Lukauskas
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001412:Bacillus subtilis; D001424:Bacterial Infections / Q000188:drug therapy / Q000662:veterinary*; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy*; D005260:Female; D008321:Mammary Glands, Animal; D008414:Mastitis, Bovine / Q000188:drug therapy*; D013381:Subtilisins / Q000302:isolation & purification / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; C061754:lysosubtilin G10X; D013381:Subtilisins